Myeloma Patient and Caregiver Survey DVRd : daratumumab + bortezomib + lenalidomide + dexamethasone |
Introduction
We need your help!
A new myeloma drug regimen, DVRd (daratumumab-bortezomib-lenalidomide-dexamethasone) will soon be undergoing review for reimbursement at the first line of therapy, for individuals with newly diagnosed transplant-eligible myeloma.Myeloma Canada is seeking information from people impacted by myeloma, so we can share their experiences with the Canadian Drug Agency’s pan-Canadian Oncology Drug Review, Expert Review Committee (pERC), and the Institut national d’excellence en santé et en services sociaux (INESSS). These organizations make funding recommendations on oncology drugs approved for sale in Canada to provincial and territorial drug programs.
Myeloma Canada provides the committees with patient and caregiver input to help reviewers understand the complexity of patients’ real-world experiences with myeloma, while ensuring our community’s needs are considered, and their voices are heard.
Myeloma Canada provides the committees with patient and caregiver input to help reviewers understand the complexity of patients’ real-world experiences with myeloma, while ensuring our community’s needs are considered, and their voices are heard.
This survey is open to people with myeloma and their caregivers who meet any of the following criteria:
- Newly diagnosed with myeloma, eligible for autologous stem cell transplant (ASCT), but have not started any treatment yet.
- Currently receiving an ASCT as their first line of myeloma treatment, or recently relapsed after first line ASCT.
- Currently receiving or have received the combination of DVRd (daratumumab-bortezomib-lenalidomide-dexamethasone) as first line treatment in conjunction with an ASCT.
As always, your input is extremely important and helps further our goal of improving Canadians' access to new myeloma treatments.
The survey should only take around 10 minutes of your time. We ask that the survey please be completed by October 9, 2024, 11:59 PM EST.If you have any questions, please write to contact@myeloma.ca and indicate “Drug Survey” in the subject line.Thank you in advance for your participation and helping your fellow Canadians impacted by myeloma!Privacy policy: All survey datum is collected by Myeloma Canada. To ensure patient and caregiver privacy and confidentiality, individual responses will not be identifiable. Please note selected quotations may be used in the final reports without reference to any identifying information.